

COPIKTRA (duvelisib)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

- 1. Relapsed or refractory chronic lymphocytic leukemia (CLL)
 - a. Patient has had at least TWO prior lines of systemic therapies
- 2. Relapsed or refractory small lymphocytic lymphoma (SLL)
 - a. Patient has had at least **TWO** prior lines of systemic therapies
- 3. Breast implant-associated anaplastic large cell lymphoma (ALCL)
- 4. Hepatosplenic T-Cell lymphoma
- 5. Peripheral T-Cell lymphoma (PTCL)

AND ALL of the following:

- 1. Prescriber agrees to monitor for serious toxicities including infections, diarrhea or colitis, cutaneous reactions, and pneumonitis
- 2. Patient will receive prophylaxis for *Pneumocystis jirovecii* (PJP)

Prior - Approval Limits

Quantity 168 capsules per 84 days

Duration 12 months

Prior – Approval Renewal Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

- 1. Relapsed or refractory chronic lymphocytic leukemia (CLL)
- 2. Relapsed or refractory small lymphocytic lymphoma (SLL)
- 3. Breast implant-associated anaplastic large cell lymphoma (ALCL)
- 4. Hepatosplenic T-Cell lymphoma
- 5. Peripheral T-Cell lymphoma (PTCL)



COPIKTRA (duvelisib)

AND ALL of the following:

- 1. NO disease progression or unacceptable toxicity
- 2. Prescriber agrees to monitor for serious toxicities including infections, diarrhea or colitis, cutaneous reactions, and pneumonitis
- 3. Patient will receive prophylaxis for *Pneumocystis jirovecii* (PJP)

Prior - Approval Renewal Limits

Same as above